참고문헌
- Fava G (2010). Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol, 1, 12-22. https://doi.org/10.4239/wjd.v1.i1.12
- Guweidhi A, Kleeff J, Giese N, et al (2004). Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis, 25, 1575-85. https://doi.org/10.1093/carcin/bgh159
- Iwata N, Yamamoto H, Sasaki S, et al (2000). Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene, 19, 5298-302. https://doi.org/10.1038/sj.onc.1203898
- Jeanteur P (2000). [14-3-3sigma (stratifin), a potential tumor suppressor frequently inactivated by methylation in cancer of the breast]. Bull Cancer, 87, 525.
- Keshamouni VG, Michailidis G, Grasso CS, et al (2006). Differential protein expression profiling by iTRAQ- 2DLC-MS/MS of lung cancer cells undergoing epithelialmesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res, 5, 1143-54. https://doi.org/10.1021/pr050455t
- Kilani RT, Maksymowych WP, Aitken A, et al (2007). Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol, 34, 1650-7.
- Lee EK, Lee YS, Lee H, Choi CY, Park SH (2009). 14-3-3epsilon protein increases matrix metalloproteinase-2 gene expression via p38 MAPK signaling in NIH3T3 fibroblast cells. Exp Mol Med, 41, 453-561. https://doi.org/10.3858/emm.2009.41.7.050
- Liang S, Xu Y, Shen G, et al (2009). Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis, 30, 4152-62. https://doi.org/10.1002/elps.200900249
- Lim JH (2003). Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol, 181, 819-27. https://doi.org/10.2214/ajr.181.3.1810819
- Martin D, Brown-Luedi M, Chiquet-Ehrismann R (2003). Tenascin-C signaling through induction of 14-3-3 tau. J Cell Biol, 160, 171-5. https://doi.org/10.1083/jcb.200206109
- Miyakawa S, Ishihara S, Horiguchi A, et al (2009). Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from, 1998 to, 2004 in Japan. J Hepatobiliary Pancreat Surg, 16, 1-7. https://doi.org/10.1007/s00534-008-0015-0
- Mosconi S, Beretta GD, Labianca R, et al (2009). Cholangiocarcinoma. Crit Rev Oncol Hematol, 69, 259-70. https://doi.org/10.1016/j.critrevonc.2008.09.008
- Nomura M, Shimizu S, Sugiyama T, et al (2003). 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem, 278, 2058-65. https://doi.org/10.1074/jbc.M207880200
- Patel T (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinomain the United States. Hepatology, 33, 1353-7. https://doi.org/10.1053/jhep.2001.25087
- Porter GW, Khuri FR, Fu H (2006). Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Seminars Cancer Biol, 16, 193-202. https://doi.org/10.1016/j.semcancer.2006.03.003
- Samuel T, Weber HO, Rauch P, et al (2001). The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem, 276, 45201-6. https://doi.org/10.1074/jbc.M106427200
- Shankardas J, Senchyna M, Dimitrijevich SD (2008). Presence and distribution of 14-3-3 proteins in human ocular surface tissues. Mol Vis, 14, 2604-15.
- Shu Y, Wang B, Wang J, Wang JM, Zou SQ (2011). Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. World J Gastroenterol, 17, 3407-19. https://doi.org/10.3748/wjg.v17.i29.3407
- Sinha P, Hutter G, Kottgen E, et al (1999). Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis, 20, 2952-60. https://doi.org/10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H
- Sugiyama A, Miyagi Y, Komiya Y, et al (2003). Forced expression of antisense 14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis, 24, 1549-59. https://doi.org/10.1093/carcin/bgg113
- Suzuki H, Itoh F, Toyota M, et al (2000). Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res, 60, 4353-7.
- Tio TL, Cheng J, Wijers OB, Sars PR, Tytgat GN (1991). Endosonographic TNM staging of extrahepatic bile duct cancer: comparison with pathological staging. Gastroenterology, 100, 1351-61.
- Todd A, Cossons N, Aitken A, Price GB, Zannis-Hadjopoulos M (1998). Human cruciform binding protein belongs to the 14-3-3 family. Biochemistry, 37, 14317-25. https://doi.org/10.1021/bi980768k
- Tompkins RK, Thomas D, Wile A, Longmire WP Jr (1981). Prognostic factors in bile duct carcinoma: analysis of 96 cases. Ann Surg, 194, 447-57. https://doi.org/10.1097/00000658-198110000-00008
- Toshima JY, Toshima J, Watanabe T, Mizuno K (2001). Binding of 14-3-3 beta regulates the kinase activity and subcellular localization of testicular protein kinase 1. J Biol Chem, 276, 43471-81. https://doi.org/10.1074/jbc.M104620200
- Tzivion G, Gupta VS, Kaplun L, Balan V (2006). 14-3-3 proteins as potential oncogenes. Seminars in cancer biology. Semin Cancer Biol, 16, 203-13. https://doi.org/10.1016/j.semcancer.2006.03.004
- Wang Y, Jacobs C, Hook KE, et al (2000). Binding of 14-3-3 beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. Cell Growth Differ, 11, 211-9.
- Wijaya I, Abdullah M (2011). Diagnosis and treatment update: cholangiocarcinoma. Acta Med Indones, 43, 212-5.
- Wilker E, Yaffe MB (2004). 14-3-3 Proteins--a focus on cancer and human disease. J Mol Cell Cardiol, 37, 633-42. https://doi.org/10.1016/j.yjmcc.2004.04.015
-
Zang D, Li X, Zhang L (2010). 14-3-3
$\zeta$ Overexpression and abnormal beta-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer. Clin Exp Med, 10, 221-8. https://doi.org/10.1007/s10238-009-0089-2 - Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell, 87, 619-28. https://doi.org/10.1016/S0092-8674(00)81382-3
- Zhai J, Lin H, Shamim M, Schlaepfer WW, Canete-Soler R (2001). Identification of a novel interaction of 14-3-3 with p190RhoGEF. J Biol Chem, 276, 41318-24. https://doi.org/10.1074/jbc.M107709200
피인용 문헌
- Proteomic analysis reveals important role of 14-3-3σ in anoikis resistance of cholangiocarcinoma cells vol.13, pp.21, 2013, https://doi.org/10.1002/pmic.201300219
- Prognostic Significance of 14-3-3γ Overexpression in Advanced Non-Small Cell Lung Cancer vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3513
- Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab vol.17, pp.1, 2015, https://doi.org/10.1186/s13075-015-0799-7
- Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications vol.36, pp.3, 2015, https://doi.org/10.1007/s13277-014-2780-5
- Decreased expression of 14-3-3 σ, an early event of malignant transformation of respiratory epithelium, also facilitates progression of squamous cell lung cancer vol.6, pp.6, 2015, https://doi.org/10.1111/1759-7714.12246
- Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1399